Theravance Biopharma Inc logo

TBPH

Theravance Biopharma Inc

$10.89

Earnings Summary

Revenue
$15.74Mn
Net Profits
$-50.19Mn
Net Profit Margins
-318.9%

Highlights

Revenue:

Theravance Biopharma Inc’s revenue jumped 248.55% since last year same period to $15.74Mn in the Q4 2018. On a quarterly growth basis, Theravance Biopharma Inc has generated 22.58% jump in its revenue since last 3-months.

Net Profits:

Theravance Biopharma Inc’s net profit jumped 42.26% since last year same period to $-50.19Mn in the Q4 2018. On a quarterly growth basis, Theravance Biopharma Inc has generated 15.56% jump in its net profits since last 3-months.

Net Profit Margins:

Theravance Biopharma Inc’s net profit margin jumped 83.44% since last year same period to -318.9% in the Q4 2018. On a quarterly growth basis, Theravance Biopharma Inc has generated 31.11% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Theravance Biopharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.01
EPS Estimate Current Year
-0.01

Highlights

EPS Estimate Current Quarter:

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.01 - a 84.43% jump from last quarter’s estimates.

EPS Estimate Current Year:

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.01.

Key Ratios

Key ratios of the Theravance Biopharma Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.11
Return on Assets (ROA)
-0.11
Return on Equity (ROE)
-0.9

Highlights

Earning Per Share (EPS):

Theravance Biopharma Inc’s earning per share (EPS) jumped 86.25% since last year same period to -0.11 in the Q2 2022. This indicates that the Theravance Biopharma Inc has generated 86.25% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Theravance Biopharma Inc’s return on assets (ROA) stands at -0.11.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Theravance Biopharma Inc’s return on equity (ROE) stands at -0.9.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-06
-0.11
-0.34
-209.09%
2022-08-08
-0.01
-0.11
-840.17%

Company Information

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Its research is focused in the areas of inflammation and immunology.

Organisation
Theravance Biopharma Inc
Headquarters
Ugland House, George Town, Cayman Islands, KY1-1104
Employees
158
Industry
Health Technology
CEO
Rick Winningham

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*